Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
RESEARCH TOOLSreports
Holding SYRE?
Track your performance easily
SYRE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.22 - $47.97
Previous Close$28.43
Volume211.49K
Average Volume (3M)573.82K
Market Cap
$1.67B
Enterprise Value$1.25B
Total Cash (Recent Filing)$414.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)3.1
Beta0.76
Next Earnings
Feb 27, 2025EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.21
Shares Outstanding51,431,220
10 Day Avg. Volume909,758
30 Day Avg. Volume573,816
Standard Deviation0.42
R-Squared0.13
Alpha-0.00520
Financial Highlights & Ratios
Price to Book (P/B)7.81
Price to Sales (P/S)1561.51
Price to Cash Flow (P/CF)-11.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.42K
Enterprise Value/Ebitda-6.17
Forecast
1Y Price Target
$54.86Price Target Upside92.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Spyre Therapeutics News
PremiumCompany Announcements
Spyre Therapeutics Faces Internal Control Challenges
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial data is expected from the Phase 1 study of SPY001 (anti-α4β7 antibody) with a focus on de-risking a potential best-in-class Q8W-Q12W dosing profile.
Financial StabilitySpyre ended 2Q24 with $426M in cash, which is still expected to fund operations well into 2027.
Pipeline DevelopmentSpyre Therapeutics' pipeline of half-life extended antibodies offering Q8-12W dosing could disrupt the inflammatory bowel disease (IBD) market, with a potential best-in-class subcutaneous (SC) dosing interval.
Bears Say
Acquisition ProspectsAbbVie, a major player in the IBD space, is now a less likely future acquirer for Spyre.
Market CompetitionThe announced deal between AbbVie and FutureGen Biopharmaceutical adds competition within the TL1A space, which is one of Spyre's three disclosed pipeline targets.
Stock PerformanceSYRE was down almost 20% while the S&P 500 was up about 1%, indicating significant underperformance.
---
Ownership Overview
9.74% Insiders
16.15% Mutual Funds
46.92% Other Institutional Investors
18.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $14.22 and its highest was $47.97 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Currently, no data Available
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$0.824 by -$0.536.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -$1.05.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 58,706,220 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$1.36 in its last earnings report, missing expectations of -$0.824. Following the earnings report the stock price went up 5.015%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Among the largest hedge funds holding Spyre Therapeutics’s share is Fairmount Funds Management Llc. It holds Spyre Therapeutics’s shares valued at 118M.
---
Spyre Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.86 (92.97% Upside)
$54.86 (92.97% Upside)
Hedge Fund Trend
Decreased
By 822.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $522.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.85%
12-Months-Change
Fundamentals
Return on Equity
-414.82%
Trailing 12-Months
Asset Growth
103.16%
Trailing 12-Months
Company Description
Spyre Therapeutics
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
---
SYRE Stock 12 Month Forecast
Average Price Target
$54.86
▲(92.97% Upside)
Technical Analysis
Best Analysts Covering SYRE
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+67.74%
reiterated a buy rating last month
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +67.74% per trade.
---